Bristol Myers Squibb (NYSE:BMY) today presented results from the EXPLORER-LTE cohort of the MAVA-LTE

[url="]Bristol Myers Squibb[/url] (NYSE: BMY) today presented results from the EXPLORER-LTE cohort o

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #Camzyos--Bristol Myers Squibb Presents Data Up to Five Ye

Bristol Myers Squibb's cardiovascular drug Eliquis is set to lose patent protection in 2028. The com

Beacon Pointe Advisors LLC acquired a new position in shares of Bristol Myers Squibb Company (NYSE:

Bank OZK bought a new stake in shares of Bristol Myers Squibb Company (NYSE: BMY) during the second

Ancora Advisors LLC purchased a new position in shares of Bristol Myers Squibb Company (NYSE: BMY) i

BMY's Camzyos gains momentum as an adolescent expansion nears an FDA decision, while rivals advance

PFE and BMY both boast strong oncology portfolios, but Pfizer's valuation and broader diversificatio

These healthcare leaders are unlikely to suspend their dividend programs.

Bristol Myers Squibb has ended its partnership with cell therapy startup Cellares to expand the manu

Benzinga readers can review the latest analyst takes on high-yielding stocks in health care sector.

J.P. Morgan's technical team sees deteriorating market internals and a pattern eerily similar to the

Barbara Oil Co. bought a new stake in Bristol Myers Squibb Company (NYSE: BMY) in the second quarter

Blue Capital Inc. acquired a new position in shares of Bristol Myers Squibb Company (NYSE: BMY) in t

BMY's legacy portfolio faces generic pressure, but stronger Eliquis sales prompt a brighter 2026 rev

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investi

Advisors Capital Management LLC purchased a new stake in shares of Bristol Myers Squibb Company (NYS

VanEck's concentrated 25-stock biotech play offers higher volatility, while iShares' broader pharma

Seaport Therapeutics just went public with a prodrug platform that has attracted board members from

SAN FRANCISCO--(BUSINESS WIRE)--Chai Discovery Announces Collaboration with Bristol Myers Squibb to

Bell and Brown Wealth Advisors LLC acquired a new position in shares of Bristol Myers Squibb Company

Bristol Myers Squibb secures FDA approval for Zenbexus (iberdomide), marking the first CELMoD therap

Bristol Myers Squibb (NYSE:BMY) today announced that the U.S. Food and Drug Administration (FDA) has

In the complaint, the Company requests, among other things: a judgment declaring that the Company do

Vinod Khosla says AI is revolutionizing drug discovery, but drug testing needs to catch up with more

China’s science surge is reshaping global drug development as Washington moves to counter Beijing’s

During market turbulence, investors turn to dividend-yielding stocks. Benzinga provides analyst rati

New State-of-the-Art Facility Will Create Nearly 500 Skilled Jobs and Accelerate the Delivery of Nex

FDA grants Replimune accelerated approval for TUDRIQEV in combination with nivolumab to treat advanc

Argus Research analyst Jasper Hellweg upgrades Bristol-Myers Squibb (NYSE:BMY) from Hold to Buy a

Citigroup analyst Geoff Meacham maintains Bristol-Myers Squibb (NYSE:BMY) with a Neutral and rais

AstraZeneca and Bristol Myers reportedly discuss a $400 billion merger as analyst assesses valuation

Crude tumbles nearly 6% after Trump cancels a strike on Iran, lifting the S&P 500 1.3% and the R

Falling Oil Please click here for an enlarged chart of United States Oil ETF (NYSE:USO). N

Bristol Myers Squibb and AstraZeneca in talks for a $400B mega-merger, potentially creating the worl

Jim Cramer senses a 'fake out' in the rumored $400B AstraZeneca and Bristol Myers Squibb meg

U.S. stock futures higher, AstraZeneca dips on merger talks, Apple down 7.4%, other stocks moving lo

Atkore Inc (ATKR) shares rise on strong Q3 results and acquisition by Prysmian for $95.00 per share.

AstraZeneca in talks to merge with Bristol Myers Squibb, creating $400B pharma giant, while talks on

RBC Capital analyst Trung Huynh maintains Bristol-Myers Squibb (NYSE:BMY) with a Sector Perform a

JP Morgan analyst Chris Schott maintains Bristol-Myers Squibb (NYSE:BMY) with a Overweight and ra

Cantor Fitzgerald analyst Carter Gould maintains Bristol-Myers Squibb (NYSE:BMY) with a Neutral a

Wells Fargo analyst Mohit Bansal maintains Bristol-Myers Squibb (NYSE:BMY) with a Equal-Weight an

FDA advisory panel backed Replimune's RP1 melanoma data ahead of the agency's August 2 decis

Guggenheim analyst Seamus Fernandez maintains Bristol-Myers Squibb (NYSE:BMY) with a Buy and rais

Bristol-Myers beats Q2 earnings and revenue estimates, driven by growth drugs, while raising its ful

US stocks gain, Dow up 300 points as tech shares surge 5.3%, Bristol-Myers Squibb beats expectation

Bristol-Myers Squibb (NYSE:BMY) raises FY2026 Adj EPS guidance from $6.05-$6.35 to $6.75-$7.00 vs $6

The CNN Money Fear and Greed index showed a sharp decline in market sentiment as stocks fell and oil